If the deal with AccessBio went sour (ie no negotiation, simply take the 7m fee), Atomo would have little relevance in the COVID landscape. No one wants the Ab tests at the moment, and the main revenue is reselling the rebranded CareStart test. Without this, the SP would be back below 20c in no time.
HIV tests and OEM aren’t exactly sexy or money makers currently. Whatever they have in development would be years away from coming to market… Atomo are at the mercy of AccessBio, so beggars can’t be choosers
AT1 FY21 - General Discussion + FA, page-1798
-
- There are more pages in this discussion • 636 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.06M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 664492 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 7674 | 2 |
View Market Depth
| Last trade - 16.12pm 16/10/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable